Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Restellini, Sophie, Afif, Waqqas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002563/
https://www.ncbi.nlm.nih.gov/pubmed/33802816
http://dx.doi.org/10.3390/jcm10061242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002563/
https://www.ncbi.nlm.nih.gov/pubmed/33802816
http://dx.doi.org/10.3390/jcm10061242

Ejemplares similares